Garscadden Pharma Ltd - Period Ending 2023-10-31

Garscadden Pharma Ltd - Period Ending 2023-10-31


Garscadden Pharma Ltd SC739479 false 2022-11-01 2023-10-31 2023-10-31 The principal activity of the company is that of a pharmacy. Digita Accounts Production Advanced 6.30.9574.0 true true SC739479 2022-11-01 2023-10-31 SC739479 2023-10-31 SC739479 core:CurrentFinancialInstruments 2023-10-31 SC739479 core:CurrentFinancialInstruments core:WithinOneYear 2023-10-31 SC739479 core:Non-currentFinancialInstruments core:AfterOneYear 2023-10-31 SC739479 core:FurnitureFittingsToolsEquipment 2023-10-31 SC739479 core:LandBuildings 2023-10-31 SC739479 core:MotorVehicles 2023-10-31 SC739479 core:OtherPropertyPlantEquipment 2023-10-31 SC739479 bus:SmallEntities 2022-11-01 2023-10-31 SC739479 bus:AuditExemptWithAccountantsReport 2022-11-01 2023-10-31 SC739479 bus:FilletedAccounts 2022-11-01 2023-10-31 SC739479 bus:SmallCompaniesRegimeForAccounts 2022-11-01 2023-10-31 SC739479 bus:RegisteredOffice 2022-11-01 2023-10-31 SC739479 bus:Director1 2022-11-01 2023-10-31 SC739479 bus:Director2 2022-11-01 2023-10-31 SC739479 bus:PrivateLimitedCompanyLtd 2022-11-01 2023-10-31 SC739479 core:Goodwill 2022-11-01 2023-10-31 SC739479 core:ComputerEquipment 2022-11-01 2023-10-31 SC739479 core:FurnitureFittingsToolsEquipment 2022-11-01 2023-10-31 SC739479 core:LandBuildings 2022-11-01 2023-10-31 SC739479 core:MotorVehicles 2022-11-01 2023-10-31 SC739479 core:OtherPropertyPlantEquipment 2022-11-01 2023-10-31 SC739479 core:PlantMachinery 2022-11-01 2023-10-31 SC739479 countries:Scotland 2022-11-01 2023-10-31 SC739479 2022-07-27 2022-10-31 SC739479 2022-10-31 SC739479 core:CurrentFinancialInstruments 2022-10-31 SC739479 core:CurrentFinancialInstruments core:WithinOneYear 2022-10-31 SC739479 core:Non-currentFinancialInstruments core:AfterOneYear 2022-10-31 iso4217:GBP xbrli:pure

Registration number: SC739479

Garscadden Pharma Ltd

Unaudited Filleted Abridged Financial Statements

for the Year Ended 31 October 2023

 

Garscadden Pharma Ltd

Contents

Company Information

1

Abridged Balance Sheet

2 to 3

Notes to the Unaudited Abridged Financial Statements

4 to 9

 

Garscadden Pharma Ltd

Company Information

Directors

Mr Ronald Adrian Badger

Mrs Lynne Barbara Badger

Registered office

3 Bank Avenue
Milngavie
Glasgow
Lanarkshire
G62 8NG

Accountants

Hamilton Morris Waugh
Chartered Certified Accountants
34 Dufferin Avenue
Bangor
Down
BT20 3AA

 

Garscadden Pharma Ltd

(Registration number: SC739479)
Abridged Balance Sheet as at 31 October 2023

Note

2023
£

2022
£

Fixed assets

 

Intangible assets

4

683,058

-

Tangible assets

5

465,913

-

 

1,148,971

-

Current assets

 

Stocks

6

42,182

2,799

Debtors

236,892

1,331

Cash at bank and in hand

 

97,663

15,239

 

376,737

19,369

Prepayments and accrued income

 

2,051

12,641

Creditors: Amounts falling due within one year

(973,770)

(32,008)

Net current (liabilities)/assets

 

(594,982)

2

Total assets less current liabilities

 

553,989

2

Creditors: Amounts falling due after more than one year

(686,079)

-

Net (liabilities)/assets

 

(132,090)

2

Capital and reserves

 

Called up share capital

7

2

2

Retained earnings

(132,092)

-

Shareholders' (deficit)/funds

 

(132,090)

2

For the financial year ending 31 October 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

All of the company’s members have consented to the preparation of an Abridged Balance Sheet in accordance with Section 444(2A) of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

 

Garscadden Pharma Ltd

(Registration number: SC739479)
Abridged Balance Sheet as at 31 October 2023

Approved and authorised by the Board on 14 May 2024 and signed on its behalf by:
 

.........................................
Mr Ronald Adrian Badger
Director

 

Garscadden Pharma Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 October 2023

1

General information

The company is a private company limited by share capital, incorporated in Scotland.

The address of its registered office is:
3 Bank Avenue
Milngavie
Glasgow
Lanarkshire
G62 8NG
Scotland

These financial statements were authorised for issue by the Board on 14 May 2024.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These abridged financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These abridged financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Going concern

The directors have reviewed the cashflow for the next 12 months and are satisfied that the company can continue as a going concern.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

 

Garscadden Pharma Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 October 2023

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Motor Vehicles

Straight Line at 25%

Office Equipment

Reducing Balance at 25%

Plant & Machinery

Straight Line at 20%

Goodwill

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date. Goodwill is amortised over its useful life, which shall not exceed ten years if a reliable estimate of the useful life cannot be made.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Goodwill

Straight Line over 10 years

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

 

Garscadden Pharma Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 October 2023

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Borrowings

Interest-bearing borrowings are initially recorded at fair value, net of transaction costs. Interest-bearing borrowings are subsequently carried at amortised cost, with the difference between the proceeds, net of transaction costs, and the amount due on redemption being recognised as a charge to the profit and loss account over the period of the relevant borrowing.

Interest expense is recognised on the basis of the effective interest method and is included in interest payable and similar charges.

Borrowings are classified as current liabilities unless the company has an unconditional right to defer settlement of the liability for at least twelve months after the reporting date.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee.

Assets held under finance leases are recognised at the lower of their fair value at inception of the lease and the present value of the minimum lease payments. These assets are depreciated on a straight-line basis over the shorter of the useful life of the asset and the lease term. The corresponding liability to the lessor is included in the balance sheet as a finance lease obligation.

Lease payments are apportioned between finance costs in the profit and loss account and reduction of the lease obligation so as to achieve a constant periodic rate of interest on the remaining balance of the liability.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

 

Garscadden Pharma Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 October 2023

3

Staff numbers

The average number of persons employed by the company (including directors) during the year, was 7 (2022 - 2).

4

Intangible assets

Total
£

Cost or valuation

Additions acquired separately

758,953

At 31 October 2023

758,953

Amortisation

Amortisation charge

75,895

At 31 October 2023

75,895

Carrying amount

At 31 October 2023

683,058

 

Garscadden Pharma Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 October 2023

5

Tangible assets

Land and buildings
£

Furniture, fittings and equipment
 £

Motor vehicles
 £

Other tangible assets
£

Total
£

Cost or valuation

Additions

411,836

8,559

27,798

26,288

474,481

At 31 October 2023

411,836

8,559

27,798

26,288

474,481

Depreciation

Charge for the year

-

1,746

3,450

3,372

8,568

At 31 October 2023

-

1,746

3,450

3,372

8,568

Carrying amount

At 31 October 2023

411,836

6,813

24,348

22,916

465,913

Included within the net book value of land and buildings above is £411,836 (2022 - £Nil) in respect of freehold land and buildings.
 

 

Garscadden Pharma Ltd

Notes to the Unaudited Abridged Financial Statements for the Year Ended 31 October 2023

6

Stocks

2023
£

2022
£

Finished goods and goods for resale

42,182

2,799

7

Share capital

Allotted, called up and fully paid shares

2023

2022

No.

£

No.

£

Ordinary shares of £1 each

2

2

2

2